Form 4: Fractyl Health Director Receives Stock Option Grant

Director Samuel Conaway was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Summary

• Director Samuel Conaway received a grant of 22,500 stock options on June 10, 2026.
• The options have an exercise price of $0.7318 per share.
• The grant is part of the standard compensation package for non-employee directors at Fractyl Health.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in minor potential dilution for existing shareholders.

Risks

• Vesting is contingent upon continued service on the board of directors.

Future Outlook

The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the biotechnology sector to ensure director retention and alignment with company performance.

Comparison to Industry Standards

• The use of annual equity grants for non-employee directors is consistent with standard practices for publicly traded life sciences companies.
• The vesting schedule tied to annual meetings is a common mechanism to ensure board continuity.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for shareholders due to the issuance of new options.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Fractyl Health, GUTS, Form 4, Director Compensation, Stock Options, Insider Transaction